Rapid Formation of Methemoglobin via Nitric Oxide Delivery for Potential Use as an MRI Contrast Agent.
Angiography
Blood
Hemoglobin
Imaging
Journal
Annals of biomedical engineering
ISSN: 1573-9686
Titre abrégé: Ann Biomed Eng
Pays: United States
ID NLM: 0361512
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
15
03
2022
accepted:
05
08
2022
pmc-release:
01
03
2024
pubmed:
17
9
2022
medline:
17
2
2023
entrez:
16
9
2022
Statut:
ppublish
Résumé
Contrast-enhanced magnetic resonance angiography is a vital tool for evaluating vascular pathology. However, concerns about the limitations and safety of gadolinium-based contrast agents have led to an interest in alternative agents. Methemoglobin (metHb) increases the T1-weighted signal intensity of the magnetic resonance image of blood and could provide a safe and effective alternative. MetHb can be produced by the reaction of nitric oxide (NO) gas with oxyhemoglobin followed by natural conversion back to hemoglobin by cytochrome b5 reductase. Since rapid production of metHb via NO has not been studied, the effectiveness of producing metHb via NO delivery to blood was evaluated using a hollow-fiber module. MetHb production began immediately and > 90% conversion was achieved within 10 min. MetHb remained stable for at least 90 min when NO delivery was removed following metHb formation. Comparison of experimental data for metHb formation with model predictions showed that only a fraction of the NO delivered was utilized for metHb production, suggesting an additional fast reaction of NO with other blood constituents. Directly delivering NO to blood for the rapid formation of metHb provides a potential platform for producing metHb as an alternative contrast agent.
Identifiants
pubmed: 36112294
doi: 10.1007/s10439-022-03049-1
pii: 10.1007/s10439-022-03049-1
pmc: PMC10422684
mid: NIHMS1922595
doi:
Substances chimiques
Methemoglobin
9008-37-1
Contrast Media
0
Nitric Oxide
31C4KY9ESH
Hemoglobins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
506-516Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Organisme : NIH HHS
ID : UL1TR002538
Pays : United States
Organisme : NIH HHS
ID : UL1TR002538
Pays : United States
Informations de copyright
© 2022. The Author(s) under exclusive licence to Biomedical Engineering Society.
Références
Ann N Y Acad Sci. 1968 Jan;146(1):119-37
pubmed: 5238627
Ann Biomed Eng. 2003 Jan;31(1):65-79
pubmed: 12572657
Front Vet Sci. 2019 Nov 26;6:416
pubmed: 32039242
J Biol Chem. 2008 Apr 11;283(15):9615-22
pubmed: 18203719
Biochemistry. 2001 Mar 20;40(11):3385-95
pubmed: 11258960
J Perinatol. 2004 May;24(5):290-4
pubmed: 15042110
Methods Enzymol. 1996;268:142-51
pubmed: 8782580
West J Med. 2001 Sep;175(3):193-6
pubmed: 11527852
Biochim Biophys Acta. 1999 May 5;1411(2-3):290-309
pubmed: 10320664
J Appl Physiol (1985). 2007 Oct;103(4):1359-65
pubmed: 17615278
Int J Mol Sci. 2021 Nov 10;22(22):
pubmed: 34830052
Br J Clin Pharmacol. 2018 Nov;84(11):2522-2534
pubmed: 30032482
Biochemistry. 2002 Feb 19;41(7):2466-74
pubmed: 11841242
Ann Biomed Eng. 2005 Feb;33(2):214-22
pubmed: 15771275
Free Radic Biol Med. 2013 Dec;65:1164-1173
pubmed: 24051181
J Cardiovasc Pharmacol Ther. 2001 Apr;6(2):163-73
pubmed: 11509923
Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):461-6
pubmed: 12524454
FEBS J. 2007 Mar;274(6):1449-58
pubmed: 17489100
Chem Res Toxicol. 1994 Jul-Aug;7(4):568-74
pubmed: 7981422
Anesthesiology. 2006 Nov;105(5):892-7
pubmed: 17065881
J Cardiovasc Magn Reson. 2005;7(4):667-9
pubmed: 16136856
Pharmacol Rev. 1991 Jun;43(2):109-42
pubmed: 1852778
Magn Reson Med. 1996 May;35(5):787-9
pubmed: 8722831
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10341-6
pubmed: 12124398
Adv Exp Med Biol. 1976;75:183-90
pubmed: 1015403
Biophys Chem. 2002 Jul 10;98(1-2):209-16
pubmed: 12128199